Previous Frame Next Frame
  • Discover: How Intrexon
    is creating the code for a
    healthier planet

    World Demand
  • Intrexon Energy Partners to
    Generate High-value Oil Products
    from Low-Cost Natural Gas

    DISCOVER

    Intrexon Energy Partners to Generate High-value Oil Products from Low-Cost Natural Gas
  • Optimizing therapeutics production:
    Improving the way we generate active pharmaceutical ingredients

    DISCOVER

    Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Intrexon and Johnson & Johnson to
    advance new hair and skin products

    DISCOVER

    Johnson & Johnson Innovation
  • Next-generation fertility solutions

    DISCOVER

    OvaScience
  • World Demand
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Medistem's Cell Platform Integrated into Intrexon's Technology Suite
  • Johnson & Johnson Innovation
  • OvaScience

UltraVector® platform to power the next generation of bio-based products
LEAP® automated purification of high value cells
RheoSwitch® precisely controlled expression
IN THE SPOTLIGHT
HEALTH
Collaboration:
Ziopharm and Intrexon are on the path to treating melanoma
FOOD
Extreme Weather:
Drought and the need for novel food applications
ENERGY
Engineering Energy:
Fueling the world with microbes
LATEST NEWS
Intrexon Announces Filing of Form S-3 Shelf Registration Statement
GERMANTOWN, Md., Sept. 5, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that, pursuant to the terms of its recent acquisition of Trans Ova Genetics, L.C., an industry-leading provider of bovine reproductive technologies, Intrexon filed a registration statement on Form S-3ASR and prospectus supplement covering the possible resale, from time to time, of shares of Intrexon's common stock received by former shareholders of Trans Ova. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer Sectors to create ...
Intrexon Announces the Appointment of Keith Canada as Vice President, UltraVector® Division
BLACKSBURG, Va., Sept. 5, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Keith Canada, Ph.D., as Vice President, UltraVector® Division, effective September 15.  He will report to Chief Operating Officer Krish Krishnan.  Dr. Canada's recruitment coincides with the recent introduction of the BeyondBio™ portal, which further expands the accessibility of Intrexon's UltraVector® platform to its diverse commercial collaborators. Dr. Canada brings to Intrexon significant experience in the biotechnology and pharmaceutical industries, including 11 years at Boehringer Ingelheim Pharmaceuticals, Inc., where he most recently...
Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients
SAN CARLOS, Calif., Sept. 2, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced that it has entered into an Exclusive Channel Collaboration (ECC) with Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: SAN and NYSE: SNY) to develop an enhanced production process for a specific family of its marketed Active Pharmaceutical Ingredients (APIs) through Sanofi's current manufacturing operations in France. This collaboration will leverage Intrexon's proprietary technology suite plus Sanofi's expertise and innovation in yeast metabolism and industrial chemistry to increase overall yield. Under the ECC, Intrexon will utilize its advance...